ClinicalTrials.gg

Program

BCD-281

A development code.

Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting, led by Biocad.

Furthest: phase 3, since Nov 17, 20251 company-led study, 1 open or runningNext primary completion: Dec 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biocad11 open or runningphase 3since Nov 17, 2025Nov 17, 2025Dec 2028phase 3 · NCT07321093

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 17, 2025First study: phase 3 study in Multiple Sclerosis, Relapsing-RemittingFirst studyNCT07321093 · 292 planned · Russia

Ahead

  1. Dec 2028Primary completion: phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT07321093

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07321093Multiple Sclerosis, Relapsing-Remitting · Russia3RecruitingDec 2028292

How it is read

Names in the registry

  • “BCD-281”, 1 entry

Codes read as this program: BCD281.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.